Supernus Pharmaceuticals, Inc. (SUPN): Price and Financial Metrics

Supernus Pharmaceuticals, Inc. (SUPN): $25.99

0.57 (-2.15%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

B

Add SUPN to Watchlist
Sign Up

SUPN Price/Volume Stats

Current price $25.99 52-week high $35.44
Prev. close $26.56 52-week low $21.99
Day low $25.53 Volume 413,800
Day high $26.59 Avg. volume 435,919
50-day MA $29.04 Dividend yield N/A
200-day MA $28.62 Market Cap 1.43B

SUPN Stock Price Chart Interactive Chart >


Supernus Pharmaceuticals, Inc. (SUPN) Company Bio


Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The company was founded in 2005 and is based in Rockville, Maryland.


SUPN Latest News Stream


Event/Time News Detail
Loading, please wait...

SUPN Latest Social Stream


Loading social stream, please wait...

View Full SUPN Social Stream

Latest SUPN News From Around the Web

Below are the latest news stories about SUPERNUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SUPN as an investment opportunity.

Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in Canada

MONTREAL, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusive license agreement with Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) ("Supernus"), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, granting Knight the rights to seek regulatory approval and commercialize Q

Yahoo | December 19, 2023

Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential

The increased understanding and widespread acceptance of mental health concerns have put psychedelic stocks in the spotlight.

Rick Orford on InvestorPlace | December 15, 2023

Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 8.7% CAGR over the last three years

It hasn't been the best quarter for Supernus Pharmaceuticals, Inc. ( NASDAQ:SUPN ) shareholders, since the share price...

Yahoo | December 4, 2023

Insider Sell Alert: Director Frederick Hudson Sells 9,093 Shares of Supernus Pharmaceuticals ...

Supernus Pharmaceuticals Inc (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, has recently seen a significant insider sell by one of its directors.

Yahoo | November 18, 2023

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2023 Earnings Call Transcript

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2023 Earnings Call Transcript November 8, 2023 Supernus Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.24, expectations were $0.13. Operator: Good afternoon, and welcome to Supernus Pharmaceuticals Third Quarter 2023 Financial Results Conference Call. At this time all participants are in a listen-only mode. Later we will conduct a […]

Yahoo | November 10, 2023

Read More 'SUPN' Stories Here

SUPN Price Returns

1-mo -10.87%
3-mo -21.19%
6-mo -4.76%
1-year -23.04%
3-year -21.69%
5-year -13.42%
YTD -10.19%
2023 -18.87%
2022 22.33%
2021 15.90%
2020 6.07%
2019 -28.60%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!